Novo Holdings A/S, 10% Owner at Avalyn Pharma Inc. (AVLN), bought 555,555 shares at $18.00 ($10.0M) on 2026-05-01, disclosed to the SEC on 2026-05-05.
Novo Holdings A/S executed the largest insider purchase in Avalyn Pharma's history by buying 555,555 shares at $18.00, signaling strong conviction in the biotech's future despite recent stock volatility. This significant capital commitment from a major shareholder suggests the company may be undervalued or poised for a major catalyst.
The stock is currently trading at $27.805, which is 8.02% below its 52-week high of $30.23 and 6.94% above its 52-week low of $26.00.
The trade represents the largest insider purchase in the company's history, potentially marking a major inflection point for the stock. Additionally, a cluster of two insider buys in the recent period suggests growing institutional support for the biotech.
The company trades at a negative forward P/E of -14.05, indicating continued losses and potential cash burn concerns for the biotech. With an industry buy percentage of only 0.53% over the last 90 days, the broader market sentiment remains cautious toward the sector.
Negative factors outweigh the positive ones.
| Filing → |
| IOBT | SELL | 2024-05-14 | $1.6M | — | Filing → |
| SPRB | SELL | 2024-03-25 | $698K | — | Filing → |
| SPRB | SELL | 2024-03-20 | $2.3M | — | Filing → |